SEOUL, South Korea, July 27, 2026
Seegene Inc., a global leader in molecular diagnostics, has introduced a comprehensive syndromic PCR testing strategy for reproductive tract infections (RTIs) by combining simultaneous detection of human papillomavirus (HPV) and sexually transmitted infections (STIs). The announcement follows the launch of the company’s Global Million Clinical Study (GMCS), an ambitious international initiative designed to generate large-scale clinical evidence that could establish a new global standard for PCR-based diagnostic testing. Supporting the initiative, Seegene analyzed approximately 60,000 HPV and STI co-testing results collected over 42 months using its proprietary STAgora™ real-time data analytics platform. The analysis revealed that STI pathogens were detected in 82% of HPV-positive cases, while HPV was identified in 46% of STI-positive cases, highlighting the strong association between concurrent infections. These findings reinforce the clinical value of comprehensive molecular testing for reproductive health, enabling healthcare professionals to identify co-infections, improve diagnostic accuracy, support early intervention, and strengthen patient management across gynecology, oncology, fertility, and infectious disease care.
Large-Scale Clinical Analysis Supports Comprehensive PCR Testing
The evidence supporting Seegene’s comprehensive testing approach is based on one of the largest internal analyses conducted using its STAgora™ statistical and clinical analytics platform. By evaluating approximately 60,000 real-world HPV and STI co-testing results, researchers identified a significant overlap between viral and bacterial reproductive tract infections. The study found that 82% of patients testing positive for HPV also carried one or more STI pathogens, while nearly half of STI-positive individuals also tested positive for HPV. Furthermore, 71% of all positive cases demonstrated simultaneous detection of both HPV and STI pathogens, emphasizing the importance of evaluating multiple infectious agents through a single molecular diagnostic test. These findings provide growing scientific support for adopting syndromic PCR testing, which enables simultaneous identification of multiple pathogens from one patient sample, improving diagnostic efficiency while reducing the possibility of missed or delayed diagnoses.
Global Million Clinical Study Aims to Establish New Standards
The Global Million Clinical Study (GMCS) represents Seegene’s long-term initiative to collect extensive clinical evidence from healthcare institutions worldwide and evaluate disease-specific molecular diagnostic strategies using real-world patient data. Through GMCS, the company plans to validate the clinical utility of combined HPV and STI testing across diverse patient populations while assessing how comprehensive pathogen detection influences clinical decision-making. Researchers believe simultaneous testing may improve the identification of asymptomatic sexually transmitted infections, support evaluation of co-infections in HPV-positive individuals, and enhance reproductive health assessments during pregnancy planning and infertility investigations. The initiative also seeks to better understand how interactions between HPV, sexually transmitted pathogens, inflammation, immune responses, and changes in the reproductive microbiome influence disease progression and patient outcomes. By generating robust multicenter evidence, Seegene aims to establish scientifically validated diagnostic strategies capable of improving reproductive health screening and precision patient care worldwide.
Advertisement
Advanced Molecular Diagnostics Expand Precision Healthcare
Seegene’s comprehensive reproductive tract infection testing strategy reflects the growing importance of multiplex molecular diagnostics in modern clinical medicine. Unlike conventional single-pathogen testing, syndromic PCR technology simultaneously identifies numerous viral, bacterial, fungal, and parasitic pathogens associated with similar clinical symptoms, enabling physicians to make faster and more informed treatment decisions. The company’s STI testing portfolio includes detection of major pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, Herpes Simplex Virus, Treponema pallidum, Gardnerella vaginalis, and Candida albicans, among others. Seegene plans to further present the scientific rationale and future clinical applications of its comprehensive HPV and STI testing strategy during ADLM 2026, reinforcing its commitment to advancing precision molecular diagnostics through evidence-based innovation. As the demand for highly accurate, multiplex diagnostic solutions continues to expand globally, Seegene’s integrated PCR platform positions the company at the forefront of improving women’s health, infectious disease diagnosis, reproductive medicine, and personalized patient management.
Source: Seegene press release
